The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Tina, Elisabet ^a,b   Lindqvist, Breezy M ^b   Gabrielson, Marike ^b   Lubovac, Zelmina ^c   Wegman, Pia ^b   Wingren, Sten ^b  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

^c UNIVERSITY OF SKÖVDE   (Sweden)

Author keywords

Breast cancer; HER2; S phase; SLC25A43

Indexed keywords

CARRIER PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SOLUTE CARRIER FAMILY 25A MEMBER 43 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST TUMOR; CELL CYCLE S PHASE; CHROMOSOME DELETION X; COMPARATIVE STUDY; COPY NUMBER VARIATION; FEMALE; GENE DELETION; GENE LOCUS; GENE SEQUENCE; GENETIC SCREENING; GENOME; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MAJOR CLINICAL STUDY; MITOCHONDRION; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR GROWTH; UTERINE CERVIX CANCER;

ADULT; AGED; BREAST NEOPLASMS; CELL PROLIFERATION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, X; DNA COPY NUMBER VARIATIONS; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEINS;

EID: 84864803696     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-350     Document Type: Article

References (33)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182. 10.1126/science.3798106, 3798106.
2. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001, 8(1):11-31. 10.1677/erc.0.0080011, 11350724.
3. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004, 5(1):63-69. 10.3816/CBC.2004.n.011, 15140287.
4. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997, 15(8):2894-2904.
5. Hartmann LC, Ingle JN, Wold LE, Farr GH, Grill JP, Su JQ, Maihle NJ, Krook JE, Witzig TE, Roche PC. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 1994, 74(11):2956-2963. 10.1002/1097-0142(19941201)74:11<2956::AID-CNCR2820741111>3.0.CO;2-V, 7954259.
6. Lantz E, Cunningham I, Higa GM. Targeting HER2 in breast cancer: overview of long-term experience. Int J Womens Health 2010, 1:155-171. 2971717, 21072285.
7. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792. 10.1056/NEJM200103153441101, 11248153.
8. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369(9555):29-36. 10.1016/S0140-6736(07)60028-2, 17208639.
9. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20(7):1800-1808. 10.1200/JCO.2002.07.058, 11919237.
10. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009, 4:127-150. 10.1146/annurev.pathol.4.110807.092311, 2710138, 18767981.
11. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275(5308):1943-1947. 10.1126/science.275.5308.1943, 9072974.
12. Parsons R, Simpson L. PTEN and cancer. Methods Mol Biol 2003, 222:147-166.
13. Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu X. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 2011, 11:11-248. 10.1186/1471-2407-11-11, 3032749, 21223585.
14. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6(2):117-127. 10.1016/j.ccr.2004.06.022, 15324695.
15. Vindelov LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983, 3(5):323-327. 10.1002/cyto.990030503, 6188586.
16. Caraux G, Pinloche S. PermutMatrix: a graphical environment to arrange gene expression profiles in optimal linear order. Bioinformatics 2005, 21(7):1280-1281. 10.1093/bioinformatics/bti141, 15546938.
17. Palmieri F. The mitochondrial transporter family (SLC25): physiological and pathological implications. Pflugers Arch 2004, 447(5):689-709. 10.1007/s00424-003-1099-7, 14598172.
18. Haitina T, Lindblom J, Renstrom T, Fredriksson R. Fourteen novel human members of mitochondrial solute carrier family 25 (SLC25) widely expressed in the central nervous system. Genomics 2006, 88(6):779-790. 10.1016/j.ygeno.2006.06.016, 16949250.
19. Schlessinger A, Matsson P, Shima JE, Pieper U, Yee SW, Kelly L, Apeltsin L, Stroud RM, Ferrin TE, Giacomini KM, et al. Comparison of human solute carriers. Protein Sci 2010, 19(3):412-428. 2866268, 20052679.
20. Ellison JW, Li X, Francke U, Shapiro LJ. Rapid evolution of human pseudoautosomal genes and their mouse homologs. Mamm Genome 1996, 7(1):25-30. 10.1007/s003359900007, 8903724.
21. Robinson AJ, Overy C, Kunji ER. The mechanism of transport by mitochondrial carriers based on analysis of symmetry. Proc Natl Acad Sci U S A 2008, 105(46):17766-17771. 10.1073/pnas.0809580105, 2582046, 19001266.
22. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971, 68(4):820-823. 10.1073/pnas.68.4.820, 389051, 5279523.
23. Staaf J, Jonsson G, Ringner M, Baldetorp B, Borg A. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 2011, 13(6):R129. 10.1186/bcr3075, 3326571, 22169037.
24. Loo LW, Wang Y, Flynn EM, Lund MJ, Bowles EJ, Buist DS, Liff JM, Flagg EW, Coates RJ, Eley JW, et al. Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women. Breast Cancer Res Treat 2011, 127(1):297-308. 10.1007/s10549-010-1297-x, 3224104, 21264507.
25. Piao Z, Malkhosyan SR. Frequent loss Xq25 on the inactive X chromosome in primary breast carcinomas is associated with tumor grade and axillary lymph node metastasis. Genes Chromosomes Cancer 2002, 33(3):262-269. 10.1002/gcc.10024, 11807983.
26. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007, 128(4):683-692. 10.1016/j.cell.2007.01.029, 17320506.
27. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010, 28(10):1057-1068. 10.1038/nbt.1685, 20944598.
28. Lindqvist BM, Farkas SA, Wingren S, Nilsson TK. DNA methylation pattern of the SLC25A43 gene in breast cancer. Epigenetics 2012, 7(3):300-306. 10.4161/epi.7.3.19064, 22430806.
29. Brown CJ. Role of the X chromosome in cancer. J Natl Cancer Inst 1996, 88(8):480-482. 10.1093/jnci/88.8.480, 8606372.
30. Mitra K, Wunder C, Roysam B, Lin G, Lippincott-Schwartz J. A hyperfused mitochondrial state achieved at G1-S regulates cyclin E buildup and entry into S phase. Proc Natl Acad Sci U S A 2009, 106(29):11960-11965. 10.1073/pnas.0904875106, 2710990, 19617534.
31. Fiermonte G, Paradies E, Todisco S, Marobbio CM, Palmieri F. A novel member of solute carrier family 25 (SLC25A42) is a transporter of coenzyme A and adenosine 3',5'-diphosphate in human mitochondria. J Biol Chem 2009, 284(27):18152-18159. 10.1074/jbc.M109.014118, 2709381, 19429682.
32. Warburg O, Wind F, Negelein E. The Metabolism of Tumors in the Body. J Gen Physiol 1927, 8(6):519-530. 10.1085/jgp.8.6.519, 2140820, 19872213.
33. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674. 10.1016/j.cell.2011.02.013, 21376230.